SRZN compared with IPSC: revenue, margins and what each company keeps, and the suppliers and customers both name

SRZNSurrozen, Inc.

Mkt capRevenueRevenue

IPSCCentury Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

SRZNSurrozen, Inc.

IPSCCentury Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

SRZN2 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Oct 21 '26±19.1%▲+0.72%×0.04

Q2 FY26—▲+18.39%—

IPSC1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±29.8%▼−4.85%×0.16

= impliedSRZN realized, solidIPSC realized, hatchedOne scale, both sides: full bar = 30%× = |realized| ÷ impliedSource: market data

SRZNSurrozen, Inc.

30.97▲+6.80%· post 30.98

Mkt cap$717.5MRevenue$5MQ2 FY26Revenue$3MFY25

IPSCCentury Therapeutics, Inc.

1.70▲+12.33%· post 1.70

ClosedNov 6 '26

Mkt cap$304.2MRevenue$109MQ1 FY25Revenue$7MFY24

Compare

ClosedNov 6 '26

SRZNSurrozen, Inc.

IPSCCentury Therapeutics, Inc.

30.97▲+6.80%post 30.98

Price

1.70▲+12.33%post 1.70

$717.5M

Mkt cap

$304.2M

Q2 FY26$5M

Revenue

$109MQ1 FY25

FY25$3M

Revenue

$7MFY24

SRZN30.97▲+6.80%vsIPSC1.70▲+12.33%ClosedNov 6 '26